JULYASIA BUSINESS OUTLOOK4 Vol 01 · Issue 2 - 1 · MAY , 2022 Publisher Alok Chaturvedi Managing Editor Emmanuel Chiristi Das Editorial Aveek Pal Chaudhuri Niveada U Sthitaprajnya Panigrahi Vishnu M Group Art Director Prabhudutta A.R.N RayEditorial queries editor@asiabusinessoutlook.comTo subscribeVisit www.asiabusinessoutlook.com/subscribe/ or send emailto subscription@asiabusinessoutlook.comCover price is $50 per issue.Editor Alok ChaturvediPrinted and Published By Alok Chaturvedi on behalf of Siliconmedia Technologies Pvt. Ltd. and Printed at Precision Fototype Services at Sri Sabari Shopping Complex, 24 Residency Road Bangalore-560025 and Published At No. 124, 2nd Floor, Surya Chambers, Old Airport Road, Murugeshpalya, Bangalore-560017.Copyright © 2022 Siliconmedia Technologies Pvt. Ltd. All rights reserved. Reproduction in whole or part of any text, photography or illustrations without written permission from the publisher is prohibited. The publisher assumes no responsibility for unsolicited manuscripts, photographs or illustrations. Views and opinions expressed in this publication are not necessarily those of the magazine and accordingly, no liability is assumed by the publisher. Design I. Dinesh Kumar Girisha MVP - Sales & Marketing Nagendra KumarCirculation Manager P MagendranEditorialThe term 'biotechnology' encompasses a wide range of procedures for modifying living things for human use, going back to the domestication of animals and the cultivation of plants, as well as 'improvements' made to these through breeding programmes that make use of artificial selection and hybridization. Modern applications include genetic engineering and cell and tissue culture techniques. Biotechnology is defined by the American Chemical Society as the use of biological organisms, systems, or processes by a variety of businesses to learn about life science and enhance the value of materials and organisms including drugs, crops, and cattle. We are seeing an exciting and increased pace of innovation as biopharmas continue to build their capabilities using tools like AI and analytics. Over the previous 15 years, acquisitions have accounted for more than 60 percent of the marketed assets of biopharma businesses, who historically have relied significantly on M&A for expansion.Biotech is doing well in these unusually difficult circumstances, in contrast to most businesses. As the worldwide pandemic spreads, executives in many other industries are growing more worried about the future of their companies. However, the effort to comprehend COVID-19 and discover treatments or preventive measures has drawn tremendous government, media, and public attention to science and health, strengthening the notion that biotech collaborations and acquisitions are wise investments. To fight the problems brought on by the COVID-19 pandemic, biotechnology products have emerged as the leading tactic. They have been able to survive the intense market rivalry in 2021 thanks to a healthy pipeline of businesses working in this sector. These players' geographic expansion, strategic partnerships, joint ventures, acquisitions, and mergers are boosting the market's expansion.Emmanuel Christi DasManaging Editoreditor@asiabusinessoutlook.comPromising Times Ahead for the Biotech Companiessiliconindia | | December 201733..ANDTAKE YOURBUSINESS TOTHE NEXTLEVEL !!Make it simple, get found byyour customers when they need you.!Visit: www.savit.in Call: +91 9699 477 488Dominate TheFirst Page Of ...
< Page 3 | Page 5 >